Creator: Help Dementia Editorial Team
Published: 2026-04-02T10:10:49

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Late dementia sits at the center of this dementia and brain health question.

LATE dementia is a neurodegenerative disease characterized by the buildup of TDP-43 protein in the brain—a pathology entirely distinct from the amyloid-beta and tau tangles associated with Alzheimer’s disease. It is the second most common neurodegenerative disease in people over 90 years old, affecting approximately 30% of those aged 85 and older, yet the majority of people who have it—and many clinicians who diagnose them—never realize it. Neurologists call LATE the most misdiagnosed form of dementia because in roughly 20% of cases initially suspected to be Alzheimer’s disease, the actual diagnosis is LATE. This article explains what LATE is, why it remains largely unrecognized despite its prevalence, how it differs clinically from Alzheimer’s, and what the 2025 diagnostic breakthrough means for patients and their families seeking accurate diagnosis and appropriate care.

What Is LATE Dementia and How Common Is It Really?
How LATE Differs from Alzheimer’s Disease in Ways Clinicians Often Miss
The Brain Pathology and Imaging Findings That Define LATE
Why Neurologists Call LATE the Most Misdiagnosed Form of Dementia
The 2025 Diagnostic Breakthrough That Changes the Game
Living with LATE—Symptoms and Disease Progression
What the Future Holds—Research and Treatment Development
Conclusion

What Is LATE Dementia and How Common Is It Really?

late stands for Limbic-Predominant Age-Related TDP-43 Encephalopathy. At its core, LATE is caused by the abnormal accumulation of a protein called TDP-43 (trans-membrane protein 43) in specific regions of the brain, particularly the limbic system—the structures involved in memory and emotion processing. This is fundamentally different from Alzheimer’s disease, which involves two different protein abnormalities: amyloid-beta plaques and neurofibrillary tangles made of tau. Because the pathology is different, the disease behaves differently, progresses at a different rate, and may eventually require different treatment approaches once therapies targeting TDP-43 become available. The prevalence of LATE is surprisingly high, yet it went largely unrecognized until researchers formally described and named it in 2019.

Today, autopsy studies show that more than 30% of brains examined from people over 80 years old contain LATE-related pathology. Among living patients aged 85 and older, approximately 30% are believed to have LATE. For those between 65 and 84 with cognitive symptoms or memory loss, the figure drops to around 10%, but this is still substantial. To put this in perspective: if LATE affects 30% of people over 85, and Alzheimer’s disease affects roughly 30-50% of the same age group, then LATE rivals or exceeds Alzheimer’s in frequency among the oldest-old. The challenge is that many people have both conditions simultaneously, which complicates diagnosis and masks LATE’s presence.

What Is LATE Dementia and How Common Is It Really?

How LATE Differs from Alzheimer’s Disease in Ways Clinicians Often Miss

While both LATE and Alzheimer’s disease cause memory loss and cognitive decline in older adults, they differ in several clinically important ways. Alzheimer’s disease typically shows a relatively rapid cognitive decline—patients may lose significant cognitive function over 5-10 years. LATE, by contrast, tends to progress more slowly. This slower rate of decline is one clue that neurologists should watch for, yet it is often mistaken for normal aging or attributed to depression or other non-neurological causes, delaying diagnosis by an average of 3.5 years. The slower trajectory can actually make LATE harder to recognize because patients and families may not perceive the changes as urgent or seek evaluation until substantial decline has already occurred.

Another critical difference lies in the pattern of brain atrophy visible on MRI scans. LATE predominantly affects the medial temporal lobe—the region containing the hippocampus (essential for forming new memories) and amygdala (involved in emotion). On brain imaging, patients with LATE often show severe atrophy or even hippocampal sclerosis (scarring and shrinkage of the hippocampus) that can be quite striking. Alzheimer’s disease, while it does affect the hippocampus, typically produces a different pattern of brain changes overall. However, here is the diagnostic trap: many patients have both LATE and Alzheimer’s pathology in their brains simultaneously, making it nearly impossible to determine which disease is driving the symptoms without specialized testing or brain examination. A patient with both conditions might show Alzheimer’s-pattern atrophy on MRI, but LATE pathology may be the primary driver of their memory problems, leading to treatment strategies that miss the actual disease.

The Brain Pathology and Imaging Findings That Define LATE

Understanding what LATE looks like under a microscope and on imaging studies helps explain why it has been so difficult to diagnose in living patients. TDP-43 protein normally resides in the cell nucleus, where it helps regulate gene expression. In LATE, TDP-43 misfolds and accumulates outside the nucleus, accumulating in the cytoplasm of neurons, particularly in the limbic structures. This accumulation damages and kills neurons over time, causing the characteristic shrinkage or sclerosis of the hippocampus and surrounding medial temporal lobe structures. On standard MRI scans, neurologists see severe atrophy of the hippocampus and amygdala—often out of proportion to atrophy in other brain regions.

some patients show a distinctive pattern called “hippocampal sclerosis,” in which the hippocampus appears shrunken and scarred. Until very recently, the only definitive way to diagnose LATE was through autopsy—examining brain tissue after death. This meant that a patient living with cognitive decline had no way to know whether they had LATE, Alzheimer’s, another form of dementia, or some combination of these. Family members and physicians operated in uncertainty, unable to predict disease progression, communicate realistic prognosis, or prepare for future care needs. However, the absence of a living diagnosis also meant that no clinical trials for LATE treatments could recruit and monitor patients effectively, slowing the development of LATE-specific therapies. The disease remained largely invisible in clinical practice and research.

The Brain Pathology and Imaging Findings That Define LATE

Why Neurologists Call LATE the Most Misdiagnosed Form of Dementia

LATE earns the label “most misdiagnosed” for several interconnected reasons. First, the disease was not formally recognized and named until 2019, meaning that neurologists trained before that time had no framework for considering LATE as a diagnosis. Second, LATE’s slower cognitive decline can be mistaken for normal aging, early mild cognitive impairment (MCI) of benign origin, or even depression—all conditions that receive different workups and management than neurodegenerative disease. Third, the overlap with Alzheimer’s disease is substantial; many patients have both diseases, and the presence of Alzheimer’s pathology on biomarker tests may cause clinicians to attribute all symptoms to Alzheimer’s while missing LATE entirely.

Fourth, and most tellingly, approximately 20% of patients initially suspected of having Alzheimer’s disease are later found to have LATE as their primary diagnosis—either through advanced biomarker testing or autopsy. This 20% figure is not trivial; it represents thousands of patients each year in the United States alone who are given an incorrect diagnosis and potentially started on treatments designed for Alzheimer’s that may not address their actual condition. A patient told they have “probable Alzheimer’s disease” and started on a medication like lecanemab (an anti-amyloid monoclonal antibody) may show little response, leaving families frustrated and confused about why the prescribed treatment isn’t working. Meanwhile, the patient’s actual condition—LATE—goes unaddressed. The slower decline of LATE can mask this diagnostic error for years, as families may simply attribute the lack of rapid progression to the medication being somewhat effective or to the patient’s individual biology.

The 2025 Diagnostic Breakthrough That Changes the Game

In January 2025, an international team of researchers led by Penn Medicine published new diagnostic criteria for LATE in *Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association*. This represents a watershed moment in dementia diagnosis. For the first time, clinical diagnostic tools now exist that enable neurologists to predict LATE in living patients, rather than waiting for a post-mortem brain examination. These criteria combine clinical features (such as the pattern of memory loss and cognitive decline), brain imaging findings (particularly the characteristic hippocampal atrophy and sclerosis), and biomarker data (blood tests that can detect TDP-43 pathology or other markers associated with LATE) to form a probabilistic diagnosis. The significance of this breakthrough cannot be overstated.

Patients and families can now potentially receive an accurate diagnosis during the patient’s lifetime, enabling informed discussions about prognosis, care planning, and research participation. Neurologists can now differentiate LATE from Alzheimer’s disease more reliably and avoid inappropriately prescribing Alzheimer’s-targeted therapies to LATE patients. Clinical trials specifically designed to test LATE treatments can now recruit and monitor patients effectively. Researchers can study the disease prospectively, following patients over time to understand how LATE progresses and which interventions might slow or halt neurodegeneration. The 2025 guidelines represent the culmination of years of international research effort and signal a fundamental shift from viewing LATE as a post-mortem diagnosis to a condition that can be recognized and managed during life.

The 2025 Diagnostic Breakthrough That Changes the Game

Living with LATE—Symptoms and Disease Progression

The primary symptom of LATE is memory loss, particularly difficulty forming new memories and recalling recent events. Patients with LATE often retain their personality, language abilities, and recognition of familiar people relatively well, at least in the earlier stages—a pattern that can differ from Alzheimer’s, where language and personality changes may emerge earlier. Because LATE progresses more slowly than Alzheimer’s disease, patients may remain relatively independent longer. A person diagnosed with LATE at age 80 might retain functional independence for 10-15 years or more, whereas Alzheimer’s disease diagnosed at the same age often leads to dependence within 5-10 years.

However, this slower progression carries a hidden burden: it means that LATE patients may live with cognitive decline for many years, watching their memory and independence gradually erode. They may be told they simply have “normal aging,” miss the window for lifestyle interventions that might slow progression, and delay important conversations with family about long-term care, finances, and end-of-life wishes. The slower decline also means that family caregivers may not recognize the severity of the situation until late in the disease course, leaving them unprepared for the eventual need for residential care or hospice services. Understanding that you have LATE rather than normal aging, while perhaps less immediately alarming than an Alzheimer’s diagnosis, is crucial for making informed decisions about your future.

What the Future Holds—Research and Treatment Development

Until now, there have been no LATE-specific treatments. This is changing. Researchers are investigating drugs and other interventions that target TDP-43 pathology, similar to how recent Alzheimer’s treatments target amyloid-beta. The fact that LATE can now be diagnosed in living patients means that clinical trials can test these experimental treatments in LATE populations specifically, rather than in mixed groups where LATE cases might be hidden among Alzheimer’s cases.

This is essential for developing therapies that work—a treatment that addresses TDP-43 might be worthless against amyloid-beta, and vice versa. Additionally, the improved ability to diagnose LATE in living patients opens the door to earlier intervention. Researchers may discover that certain lifestyle changes, cognitive training, medications, or other strategies can slow LATE’s progression—interventions that only work if applied before significant neuronal loss has already occurred. The next decade will likely see a substantial expansion in LATE research and a growing number of treatment options. For patients and families facing a LATE diagnosis today, this means that the course of the disease is not entirely fixed; new interventions may become available as the patient progresses through their illness.

Conclusion

LATE dementia is a common, under-recognized form of neurodegeneration that has been called the most misdiagnosed form of dementia because it is so frequently confused with Alzheimer’s disease. Affecting about 30% of people over 85 and approximately 20% of those with a suspected Alzheimer’s diagnosis, LATE is caused by accumulation of TDP-43 protein in the brain’s limbic structures and progresses more slowly than Alzheimer’s disease. Until 2025, diagnosis required a post-mortem brain examination, leaving living patients and their clinicians operating without certainty.

The new diagnostic criteria published in January 2025 have changed this landscape, enabling neurologists to identify LATE during a patient’s lifetime using clinical, imaging, and biomarker information. If you or a family member has been diagnosed with dementia or cognitive decline, asking whether LATE has been considered is a reasonable question to raise with your neurologist. Accurate diagnosis is the foundation for appropriate care, realistic prognostication, and access to clinical trials testing new treatments. As LATE-specific therapies continue to emerge from research pipelines, getting the diagnosis right today becomes even more important for tomorrow’s treatment options.